Wearable Device Could Shed Light on Parkinson & #039;s Disease

Currently, there are no universal objective metrics and target ranges for assessing or managing Parkinson’s disease (PD) that can be used in the same way that cholesterol or blood sugar levels, peak flow measures or blood pressure readings, for example, are used to manage other common chronic conditions.  Global Kinetics Corporation (GKC) is trying to change that by conducting a randomized and controlled study to evaluate the widespread implementation of target ranges derived from its wearable device, the Personal KinetiGraph (PKG). The target ranges could dictate treatment decisions for PD. The PKG monitors symptoms of PD patients throughout the day. The Melbourne, Australia-based company has received $350,000 worth of funding and support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), Shake It Up Australia Foundation, and Parkinson’s Victoria for the 225-patient Treat-to-Target study. “The importance of the current project being pursued is not around validating the PKG technology,” Michelle Goldsmith, senior vice president, business development and legal affairs of GKC, told MD+DI. “It’s about providing reference targets for Parkinson’s treatment. I think for us that’s really important and groundbreaking research. It’s an incredibly exciting project and it’s a great opportunity for us to work with well-recognized and well-respected partners.” The Treat-to-Target study has already commenced in a number of Australian clinical ...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news